Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Key Inclusion Criteria:

• Histologically confirmed, locally advanced (unresectable) or metastatic nonsquamousNSCLC

• Documented absence of tumor activating EGFR mutation, ALK gene and ROS1rearrangements, and alterations in any actionable driver oncogenes for which thereare locally approved targeted first-line therapies

• PD-L1 IHC testing documenting TPS < 49%

• No prior systemic treatment for advanced/metastatic NSCLC.

• Measurable disease by RECIST 1.1

• ECOG performance status score of 0 or 1

• Life expectancy ≥ 3 months

• Adequate liver, kidney, thyroid and bone marrow function

Key Exclusion Criteria:

• Have known active central nervous system metastases and/or carcinomatous meningitis.Patients with treated brain metastases may participate, provided they areradiologically stable

• Active known or suspected autoimmune disease

• Has any condition requiring systemic treatment with corticosteroids, prednisoneequivalents, or other immunosuppressive medications within 14 days prior to firstdose of study drug

• Interstitial lung disease that is symptomatic

• Known human immunodeficiency virus (HIV) positive with CD4+ T-cell (CD4+) count < 350 cells/μL, or an HIV viral load greater than 400 copies/mL, or a history of anacquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, or not on established antiretroviral therapy (ART) for at least 4 weeksprior to initiation of study drug dosing. (HIV positive subjects who do not meetthese exclusion criteria are eligible)

• Positive test for hepatitis C RNA (a patient who is hepatitis C virus [HCV] antibodypositive but HCV RNA negative due to documented, curative prior antiviral treatmentor natural resolution is eligible)

• Positive test for hepatitis B surface antigen or hepatitis B core antibody (hBcAb) (a patient whose hBsAg is negative and hBcAb is positive may be enrolled if ahepatitis B virus (HBV) DNA test is negative and the subject is retested for HbsAgand HBV DNA every 2 months)

• History or evidence of any clinically unstable/uncontrolled disorder, condition, ordisease (including, but not limited to, cardiopulmonary, renal, metabolic,hematologic, or psychiatric) other than NSCLC, that, in the opinion of theInvestigator, would pose a risk to patient safety or interfere with studyevaluations, procedures, or completion

Other protocol defined inclusion/exclusion criteria apply.